KATHERINE Trial: Long-Term Outcomes of T-DM1 vs Trastuzumab in HER2+ Breast Cancer with Residual Disease
Dr. Tarantino summarize the trial's design comparing adjuvant T-DM1 versus trastuzumab for residual invasive disease post-neoadjuvant therapy. Discussions include efficacy comparisons, recent 5-year OS analysis results, and the significant IDFS benefits observed with T-DM1 over an 8+ year follow-up period.
Video content above is prompted by the following:
- Please summarize the KATHERINE trial design, which studied adjuvant T-DM1 versus trastuzumab for residual invasive disease after neoadjuvant therapy.
- How did efficacy data compare amongst the treatment arms?
- How did the recent 5-year OS analysis results presented at SABCS 2023 compare between arms?
- Please comment on the 8+ year follow up data, including IDFS data from this analysis.
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
